Klotho Neurosciences, Inc.
NASDAQ: KLTOW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joseph A. Sinkule
- Employees
- 3
- Headquarters
- Omaha, United States
- IPO year
- 2022
- Market cap
- $6.3M
- Website
- https://klothoneuro.com
Loading KLTOW…
Loading profile data…Frequently asked questions about KLTOW
What does Klotho Neurosciences, Inc. (KLTOW) do?
Klotho Neurosciences, Inc. is a biopharmaceutical company focused on developing medical treatments for a variety of severe illnesses, including cancer, heart disease, and conditions affecting the nervous system. Among its key product initiatives are gene therapy candidates: AMI-101, designed for either preventing or treating Alzheimer's disease,...
Where does KLTOW trade?
Klotho Neurosciences, Inc. (KLTOW) trades on the NASDAQ Global Market.
What sector is KLTOW in?
Klotho Neurosciences, Inc. (KLTOW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Klotho Neurosciences, Inc.?
Joseph A. Sinkule is the chief executive officer of Klotho Neurosciences, Inc. (KLTOW).
Where is Klotho Neurosciences, Inc. headquartered?
Klotho Neurosciences, Inc. is headquartered in United States.
Does KLTOW pay a dividend?
Klotho Neurosciences, Inc. (KLTOW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KLTOW go public?
Klotho Neurosciences, Inc. (KLTOW) completed its initial public offering in 2022.